For the quarter ending 2025-09-30, INBX had -$33,479K decrease in cash & cash equivalents over the period. -$33,834K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -35,256 | -71,965 |
| Depreciation and amortization | 583 | 1,336 |
| Accretion of debt discount and non-cash interest expense | 638 | 1,159 |
| Stock-based compensation expense | 3,175 | 5,220 |
| Non-cash lease expense | 456 | 878 |
| Loss on disposal of fixed assets | -3 | - |
| Non-cash gain on transaction with acquirer | 0 | 0 |
| Accounts receivable | -127 | -119 |
| Other receivables | -3 | 689 |
| Receivables from related parties | 0 | -23 |
| Prepaid expenses and other current assets | -25 | -952 |
| Other non-current assets | 22 | -22 |
| Accounts payable | -1,519 | -953 |
| Accrued expenses | -1,515 | -1,412 |
| Operating lease liability | -522 | -538 |
| Net cash used in operating activities | -33,824 | -65,848 |
| Purchase of fixed assets | 10 | 21 |
| Proceeds from the sale of property and equipment | 3 | - |
| Net cash used in investing activities | -7 | -21 |
| Proceeds from the issuance of debt | 0 | 99,965 |
| Payment of fees associated with debt | 0 | 125 |
| Proceeds from the exercise of stock options | 352 | 0 |
| Net cash provided by financing activities | 352 | 99,840 |
| Net increase (decrease) in cash and cash equivalents | -33,479 | 33,971 |
| Cash and cash equivalents at beginning of period | 152,596 | - |
| Cash and cash equivalents at end of period | 153,088 | - |
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)